ADHD Medication: An Overview of the Classes

Medication is the part of ADHD that generates the most heat and the least clarity. This page does something narrow and deliberately unexciting: it describes what the categories of medicine are, so that a reader can follow a conversation with a prescriber. It does not recommend medication, does not argue against it, and contains no doses, schedules or instructions.

Whether medication is appropriate for a particular person is a clinical decision that depends on age, symptom pattern, other conditions, other medicines, family history and preference. No web page can make it.

Two Broad Categories

Medicines used in ADHD fall into two groups: stimulants and non-stimulants. Stimulants have the longer history and are generally described as first-line for most patients; non-stimulants are typically considered where stimulants are unsuitable, poorly tolerated or insufficiently effective, or where other circumstances make them preferable.

Stimulant Medicines

Two chemical families account for essentially all stimulant prescribing.

Methylphenidate. In use for ADHD since the mid-twentieth century and among the most studied medicines in paediatrics. Covered in detail on the methylphenidate page; the authoritative reference is MedlinePlus.

Amphetamine-class medicines. Including dextroamphetamine and mixed amphetamine preparations. Covered on the amphetamine-class page, with MedlinePlus references for dextroamphetamine and combined dextroamphetamine and amphetamine preparations.

Both families are available in shorter-acting and longer-acting formulations. The practical difference is how long an effect lasts and how many times a day something must be taken — relevant, for example, to whether a dose falls during the school day. Which formulation suits someone is a prescribing matter.

Both are controlled substances in the United States, reflecting recognised potential for misuse and dependence. This has real consequences for how prescriptions are issued and refilled, and it is one reason storage and supervision are discussed at the outset. The history page explains how the current range came about.

Non-Stimulant Medicines

Several non-stimulant options exist. Atomoxetine is the most established; unlike stimulants it is not a controlled substance, and it is typically described as taking longer to reach full effect. MedlinePlus maintains the reference page for atomoxetine, including its warnings, which a prescriber will discuss.

Certain medicines developed for other purposes are also used in ADHD in some circumstances. Which are appropriate depends heavily on the individual clinical picture.

What Monitoring Usually Involves

Medication for ADHD is not typically a matter of a single prescription. Ongoing review is standard practice and usually includes:

• Review of whether the medicine is helping with the specific difficulties it was started for
• Review of side effects, including ones the patient may not volunteer — sleep and appetite in particular
• Routine physical measurements, which for children commonly includes growth
• Feedback from school or work about whether anything has changed where it matters
• Periodic reconsideration of whether the medicine is still needed

Reporting side effects to the prescriber is the expected path. Medicines are frequently adjusted, and a difficulty with one option does not imply a difficulty with all of them.

What Medication Is and Is Not Expected to Do

Medication in ADHD is described in clinical guidance as symptom management rather than cure, and effects generally last while the medicine is active. This is why it is normally considered as one component of a broader plan rather than the whole of it — the range of approaches page covers what else is usually involved, and the school support page covers the educational side, which medication does not address by itself.

Where to Read Further

For any specific medicine, the reliable reference is the MedlinePlus drug page, which sets out uses, precautions, side effects and what to discuss with a prescriber. The American Academy of Pediatrics publishes the guidance most commonly followed for children and adolescents, and NIMH maintains a general overview.